Dr Guy Pratt MD FRCP FRCPath

Image of Dr Guy Pratt

Institute of Immunology and Immunotherapy
Honorary Senior Lecturer
Consultant Haematologist at UHB NHS Foundation Trust

Contact details

Telephone
+44 (0)121 424 3698
Fax
+44 (0)121 766 7530
Email
g.e.pratt@bham.ac.uk
Address
Institute of Immunology and Immunotherapy
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Guy Pratt is an Honorary Senior Lecturer at the University of Birmingham and a Consultant Haematologist at University Hospitals Birmingham NHS Foundation Trust.

Dr Pratt has been a Consultant Haematologist in Birmingham since 2001 initially as a clinical academic working in the School of Cancer Sciences in the University of Birmingham/Heart of England NHS Trust and more recently as a Consultant Haematologist at University Hospitals Birmingham. His main research interests are multiple myeloma and chronic lymphocytic leukaemia (CLL) both supporting laboratory research and clinical trials.  He is a trustee for the British Society of Haematology and Waldenstroms UK. He has developed a large number of collaborations nationally with a growing publication output and is currently lead for developing and promoting guidelines relating to plasma cell disorders for the UK Myeloma forum including clinical lead for the 2016 NICE myeloma guidelines.

Qualifications

  • MD, University of Cambridge, 2000
  • FRCPath, Royal College of Pathologists, 2000
  • FRCP, Royal College of Physicians, 1993
  • MBBChir, Cambridge University, 1989

Biography

Dr Pratt has been a Consultant Haematologist in Birmingham since 2001 initially as a clinical academic working in the School of Cancer Sciences in the University of Birmingham/Heart of England NHS Trust and more recently as a Consultant Haematologist at University Hospitals Birmingham. His main research interests are multiple myeloma and chronic lymphocytic leukaemia (CLL) both supporting laboratory research and clinical trials.  He is a trustee for the British Society of Haematology and Waldenstroms UK. He has developed a large number of collaborations nationally with a growing publication output and is currently lead for developing and promoting guidelines relating to plasma cell disorders for the UK Myeloma forum including clinical lead for the 2016 NICE myeloma guidelines.

Teaching

  • Personal mentor/SSC mentor (Student selected component) for 15 medical students (shared with a colleague). This involves 1:1 and group meetings throughout the year, mentoring of students as required and acting as a supervisor for audits and electives.
  • Developed an annual teaching module for the SSM2 module for second/third year medical students since 2012 entitled “Management of Haematological malignancies” that involves developing a programmed module, supervising and marking student presentations and a written project. Drs Raghavan, Kinsella and Malladi at the QE are co-supervisors on this module.
  • Examined for the 5th year OSCE exams annually since 2011 (including resits in 2014), the 4th year OSCE exams annually since 2013 and the 4th year conference poster presentations annually. Marked or examined several intercalated medical student degrees (including in Leicester 2013).
  • Examined as an external examiner for an MD thesis in Cardiff (twice in 2006 and 2011) and at The Royal Marsden (2011), as an internal examiner for an MSc in Oncology in Cancer Studies (2009), and co-supervised a post graduate student MPhil degree 1/11/05-1/11/07 (accepted in 2008).
  • Supervised a biosciences undergraduate MSci project involving a 20 week laboratory based myeloma research project.
  • Nominated for Recognising Excellence in Medical Education (REME) teaching award for the academic year 2008/2009.
  • Lectures regularly on the MSc in Oncology, BMed Sci and BOP courses at the University and has regularly lectured to nurses and professions allied to medicine.
  • Lectured 6 times to patients and relatives on Myeloma Info days organised by Myeloma UK, presented at an annual Waldenstroms patient day in London in 2012, 2013 and Birmingham 2015 and given numerous talks to patient support groups and LLR patient days.

Postgraduate supervision

Dr Pratt is a PhD co-supervisor (with Prof Moss) for Dr Helen Parry and PhD co-supervisor for Dr Phillip Nicolson (with Prof Watson) and hase supervised MSc and MPhil projects previously. He examined two PhDs in 2014 – Ka Yu Yeung (Warwick University) and Gill Lowe (University of Birmingham) in 2015.

If you are interested in studying with Dr Pratt please contact him on the contact details above, or for any general doctoral research enquiries, please email: dr@contacts.bham.ac.uk or call +44 (0)121 414 5005.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research

Dr Pratt has over 110 peer reviewed journal publications. His main research interests are multiple myeloma and chronic lymphocytic leukaemia. He has lectured nationally and internationally on several occasions on multiple myeloma and CLL and speak at patient seminars. Nationally, he has led guideline development for plasma cell disorders including the recently published NICE myeloma guideline. He has chaired meetings of local scientists and physicians with an interest in myeloma and chronic lymphocytic leukaemia and is on the steering group for the Central England Haemato-Oncology Research Biobank.

Dr Pratt was Chief Investigator for a national trial called PICCLE looking at a parp inhibitor drug, olaparib, in relapsed CLL that opened in 2011 in 12 UK centres. He is a co-investigator for the TEAMM trial, MUK9 and BAP trials, a member of the Trial Management Group for a national randomised phase II trial in Waldenstrom’s Macroglobulinaemia and on the data monitoring committee for the LenaRIC trial and HA-1 trials; he has also been Principal Investigator or over 20 trials.

Main Research Interests
  • T cell immunity and immunotherapy and multiple myeloma and the premalignant MGUS (Prof Paul Moss)
  • T cell immunity and the effect of CMV in CLL (Prof Paul Moss)
  • Examining the role of metabolomics and hypoxia in multiple myeloma and MGUS bone marrows (Dr Dan Tennant)
  • Telomere dysfunction in CLL, MGUS and multiple myeloma (Dr Chris Pepper, Prof Chris Fegan, Dr Duncan Baird, Cardiff University, Dr Jim Allan, Newcastle University)
  • Biology of ATM mutated CLL and Multiple Myeloma (Prof Stankovic/Prof Taylor). The PICCLE trial very much arose from their laboratory work together with the development of olaparib by Kudos/Astra Zeneca. T cell immunity in CLL (Prof Moss, Dr Helen Parry).
  • Bezafibrate and medroxyprogesterone and other novel agents in CLL in vitro (Prof Bunce, Prof Drayson)
  • Immune targeting of the phosphoproteome in chronic lymphocytic leukaemia (Dr Mark Cobbold)
  • Investigating the role of Mcl-1, Zap-70, NF-kb, BCR signalling, CD38 and telomere dysfunction in CLL biology (Prof Chris Fegan, Dr Chris Pepper, Dr Paul Brennan, Dr Duncan Baird all at University of Wales, Cardiff)
  • Investigating polymorphisms in CLL and multiple myeloma particularly within the glutathione gene and IRF4 genes (Dr Jim Allan, Newcastle University, and Dr David Allsup, Hull Royal Infirmary)
  • Assessment of serum biomarkers in CLL (Professor David Oscier, Bournemouth)
  • UK-wide genome association studies in CLL and myeloma (Professor Richard Houlston, Institute for Cancer Research, Royal Marsden)
  • Serum free light chains (Binding Site UK Ltd, Birmingham, UK) - Dr Pratt has collaborated on research on serum free light chains with the Binding Site UK Ltd a Birmingham based company over a number of years. He is on the Medical Advisory Board and has spoken at their biennial national meetings held in Bath (2010, 2008) and Warwick (2006, 2004).

Other activities

  • Member of the International Myeloma Working Group (2014-) 
  • Secretary for the Haemato-Oncology Task force for the British Committee for Standards in Haematology (2014-)
  • Trustee for the British Society of Haematology (2014-)
  • Trustee of the Waldenstrom’s UK forum (UKWMF) (2013-)
  • Clinical Lead for NICE myeloma guideline group for NICE October 2013 – February 2016
  • Chair for the UK Multiple Myeloma Forum Guidelines Group from July 2011 (previously secretary)
  • Member of the executive committee of the UK Myeloma Forum (2011-)
  • Training representative for the Myeloma subgroup of the Genomic’s England project

Publications

Pratt G (2016) Panobinbostat plus bortezomib and dexamethasone for relapsed myeloma. Lancet Haematol [Epub ahead of print]

Pratt G (2016) A selective histone deacetylase inhibitor for myeloma. Lancet Oncology [Epub ahead of print]

McNee G, Eales KL, Wei W, Williams DS, Barkhuizen A, Bartlett DB, Essex S, Anandram S, Filer A, Moss PA, Pratt G, Basu S, Davies CC and Tennant DA (2016) Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. Leukemia [Epub ahead of print]

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A and Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 3(7):e340-51

Parry H, Damery S, Hudson C, Maurer M, Cerhan J, Pachnio A, Begum J, Slager S, Fegan C, Pepper C, Shanafelt T, Pratt G and Moss P (2016) Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. Am J Hematol 91(8):776-81

Parry HM, Zuo J, Frumento G, Mirajkar N, Inman C, Edwards E, Griffiths M, Pratt G and Moss P (2016) Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years. Immun Ageing 13:1

Pratt G, Thomas P, Marden N, Alexander D, Davis Z, Hussey D, Parry H, Harding S, Begley J and Oscier D (2016) Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival. Leuk Lymphoma 57(10):2342-50

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P and Stankovic T (2016) ATR inhibition induces synthetic lethality and overcomes c chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood 127(5):582-95

Oldreive CE, Skowronska A, Davies NJ, Parry H, Agathanggelou A, Krysov S, Packham G, Rudzki Z, Cronin L, Vrzalikova K, Murray P, Odintsova E, Pratt G, Taylor AM, Moss P and Stankovic T (2015) T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice. Dis Model Mech 8(11):1401-12

Koczula KM, Ludwig C, Hayden R, Cronin L, Pratt G, Parry H, Tennant D, Drayson M, Bunce CM, Khanim FL and Günther UL (2016) Metabolic plasticity in CLL: Adaptation to the hypoxic niche. Leukemia 30(1):65-73